<DOC>
	<DOCNO>NCT00845221</DOCNO>
	<brief_summary>It phase 4 study , randomise multicentric . Within 2 month diagnosis , patient daily receive imatinib oral way least 1 year ( 260mg/m² day ) , i.e . cytogenetic analysis . Beyond 1 year treatment , haematological relapse loss cytogenetic response observe , nature treatment suggest patient left appreciation investigator . Later , discontinuation imatinib discuss molecular remission ( negative RT-PCR ) obtain maintain least 2 year .</brief_summary>
	<brief_title>Glivec Pediatric Chronic Myeloid Leukemia ( CML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Old &lt; 18 year , male female . Chronic myeloid leukaemia confirm cytogenetic level presence translocation ( 9 ; 22 ) ( q34 ; q11 ) presence transcript BCRABL event absence description translocation ( 9 ; 22 ) ( q34 ; q11 ) . Chronic phase chronic myeloid leukaemia Absence extramedullary disease ( except hepatomegaly and/or splenomegaly ) . Absence former treatment chronic myeloid leukaemia except hydroxyurea . Stop hydroxyurea least week begin imatinib mesylate . Diagnosis chronic myeloid leukaemia chronic phase recent ( less 2 month ) . Score Lansky ≥ 60 . Effective contraception among patient age procreate . Written voluntary inform consent two parent legal guardian . Patients grade 3 / 4 cardiac disease . Pathology cardiac , pulmonary , hepatic , renal neurological grade &gt; 2 ( WHO ) . Participation clinical trial 28 day precede begin treatment . Impossible Followup least 2 year , patient compliant . Expectant mother nursing .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>